Specialist gives pearls on ocriplasmin use

HAMBURG — Clinical trials on ocriplasmin, including subgroup analysis of best responders, have shown patient selection plays a crucial role in the success of the therapy and may account for discrepancies in response rate from site to site, according to a speaker here.“Ocriplasmin is not the same as other intravitreal injections we are currently utilizing in clinical practice. Who and how we inject may be important,” Baruch Kuppermann, MD, said at the Euretina meeting. 

Full Story →